The Netherlands: Leyden Labs takes US$140m in a Series B financing for new approach to combat viruses

Amsterdam-based Leyden Laboratories, a biotech company developing products that protect from known and new respiratory viruses, has closed a US$140m Series B financing round to bring the total raised in 2021 to approximately US$200m. The round was led by Series A investors Casdin Capital and GV (formerly Google Ventures) with participation from incoming investors SoftBank…

You must be a HMI Subscriber to view this content.

Subscribe Now »